These cancers then commandeer the canonical TGFβ pathway to promote epithelial-to-mesenchymal transition (EMT), modulate the extracellular environment (ECM), and decrease immune surveillance, leading to metastasis and treatment resistance3,4,8–12. This evidence concerns the gene TGFB1 and cancer.